We do expect some selling of Array today after AstraZeneca’s announced negative results from Phase 3 SELECT-1 trial of the MEK inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment for KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). The results did not meet the trial’s primary endpoint of progression-free survival (PFS), and did not demonstrate overall survival (OS).
These results, we decided, will not distract us into forgetting the great news about Array’s drug binimetinib in NRAS-mutant melanoma. The results met . . .
This content is for paid subscribers.
Today’s Highlights August 9, 2016